A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Allakos Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 35,100 shares of ALLK stock, worth $47,385. This represents 0.0% of its overall portfolio holdings.

Number of Shares
35,100
Previous 30,500 15.08%
Holding current value
$47,385
Previous $38,000 7.89%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.0 - $1.45 $4,600 - $6,670
4,600 Added 15.08%
35,100 $35,000
Q1 2024

May 15, 2024

BUY
$1.02 - $3.23 $714 - $2,261
700 Added 2.35%
30,500 $38,000
Q4 2023

Feb 14, 2024

SELL
$1.72 - $3.18 $19,780 - $36,570
-11,500 Reduced 27.85%
29,800 $81,000
Q3 2023

Nov 14, 2023

SELL
$2.13 - $5.55 $38,553 - $100,455
-18,100 Reduced 30.47%
41,300 $93,000
Q2 2023

Aug 14, 2023

SELL
$3.6 - $5.25 $69,840 - $101,850
-19,400 Reduced 24.62%
59,400 $258,000
Q1 2023

May 15, 2023

SELL
$4.3 - $8.27 $112,660 - $216,674
-26,200 Reduced 24.95%
78,800 $350,000
Q4 2022

Feb 14, 2023

SELL
$5.66 - $8.42 $623,166 - $927,042
-110,100 Reduced 51.19%
105,000 $884,000
Q3 2022

Nov 14, 2022

SELL
$3.02 - $6.12 $2.11 Million - $4.28 Million
-698,600 Reduced 76.46%
215,100 $1.32 Million
Q2 2022

Aug 15, 2022

BUY
$2.6 - $6.14 $763,620 - $1.8 Million
293,700 Added 47.37%
913,700 $2.86 Million
Q1 2022

May 16, 2022

BUY
$5.08 - $9.81 $3 Million - $5.79 Million
589,800 Added 1952.98%
620,000 $3.53 Million
Q4 2021

Feb 14, 2022

SELL
$8.55 - $111.89 $44,460 - $581,828
-5,200 Reduced 14.69%
30,200 $296,000
Q3 2021

Nov 15, 2021

SELL
$76.53 - $110.43 $3.41 Million - $4.91 Million
-44,500 Reduced 55.69%
35,400 $3.75 Million
Q2 2021

Aug 16, 2021

BUY
$85.37 - $114.1 $2.77 Million - $3.71 Million
32,500 Added 68.57%
79,900 $6.82 Million
Q1 2021

May 17, 2021

BUY
$109.73 - $153.66 $5.2 Million - $7.28 Million
47,400 New
47,400 $5.44 Million

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $114M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.